ACCELERATE: Intracerebral hemorrhage

Median time to achieve target SBP range was 5.5 minutes5

All patients achieved target SBP within 30 minutes5

  • 96.9% achieved target SBP with CLEVIPREX monotherapy5
  • Mild/moderate hypotension was reported in 3 patients and resolved with dose reduction or drug discontinuation5

Mean (±SE) change in SBP with clevidipine (mITT population=33).
Mean baseline SBP=186 mm Hg.

CLEVIPREX is not indicated for the prevention or treatment of stroke.

What AIS Guidelines say to look for in BP control

Since 2018, the Guidelines for the Early Management of Patients With Acute Ischemic Stroke (AIS) have recommended CLEVIPREX as an option for lowering arterial hypertension before, during, and after acute reperfusion therapy. View more

ACCELERATE (ICH) Study Design5

Study type Multicenter, prospective, open-label, pilot, phase 3b study
Divider
Purpose Evaluate the efficacy and safety of CLEVIPREX in managing hypertension (SBP >160 mm Hg) in patients presenting within 6 or 12 hours of symptom onset with ICH
Divider
Patient population N=35
Divider
Key inclusion criteria
  • Computed tomography evidence of ICH
  • Presentation within 12 hours of ICH symptom onset
  • SBP >160 mm Hg
Divider
Protocol7
  • CLEVIPREX was initiated at 2 mg/h and titrated every 90 seconds until SBP <160 mm Hg was achieved
  • CLEVIPREX was titrated to maintain SBP within the specified target range (140-160 mm Hg) for a minimum of 30 minutes to a maximum of 96 hours
  • BP was monitored continuously via arterial line